Sun Pharmaceutical’s Psoriasis Candidate Shines in Phase 3 Trials

Sun Pharmaceutical Industries saw positive results in two Phase 3 trials assessing its psoriasis candidate tildrakizumab, with the product meeting its primary endpoints for efficacy and safety.

According to the company, the candidate’s overall safety profile in both trials was consistent with data in previous studies.

Both studies tested the drug in patients with moderate-to-severe plaque psoriasis, the company said last week.